NICE changes it’s tune about cabazitaxel

According to news reports this morning, the National Institute for Health and Care Excellence (NICE) in England has changed its tune about covering cabazitaxel (Jevtana) as a treatment for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ NORE …

NICE approves use of Zytiga prior to chemotherapy

New guidance in England has expanded coverage of treatment with abiraterone acetate (Zytiga) + prednisone for men with metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …

Xtandi beats out Zytiga in NICE evaluation in the UK

According to an article this morning on the PharmaTimes web site,  Astellas has convinced the National Institute for Health and Care Excellence (NICE) to recommend coverage of enzalutamide (Xandi) in chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

NICE rejects coverage of enzalutamide in men with chemo-naive mCRPC

According to a report on Yahoo!News, the National Institute for Care and Health Excellence (NICE) in the UK has issued draft guidance suggesting that enzalutamide is not sufficiently cost-effective for use in the treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

NICE recommends coverage of radium-223, but …

According to a recent report in Pharma Times, the National Institute for Health and Care Excellence (NICE) in the UK is recommending coverage of treatment with radium-223 dichoride (Xofigo) but has changed its mind about coverage of degarelix (Firmagon). … READ MORE …

NICE rejects Dendreon’s Provenge … again

According to a report on the PharmaFile web site, the National Institute for Health and Care Excellence (NICE) in England has rejected Dendreon’s application for coverage of the costs of treatment with sipuleucel-T (Provenge) for the second time in less than a year. … READ MORE …

Access to, cost of, and value of high-price prostate (and other) cancer drugs

As all our regular readers will be well aware, it is not enough, in the UK, for a new cancer drug to be approved for use by the European Union and its European Medicines Agency. … READ MORE …